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OBJECTIVE—Animal studies suggest that low serum 25-hydroxyvitamin D (25[OH]D) may
impair insulin synthesis and secretion and be involved in the pathogenesis of diabetes. Results
in studies in humans have not been consistent, however. Prediabetes is a stage earlier in the
hyperglycemia/diabetes continuum where individuals are at increased risk of developing diabe-
tes and where prevention efforts have been shown to be effective in delaying or preventing the
onset of diabetes. However, previous studies have not examined the association between low
serum 25(OH)D levels and prediabetes.
RESEARCH DESIGN AND METHODS—We examined the 12,719 participants (52.5%
women) in the third National Health and Nutrition Examination Survey aged .20 years who
were free of diabetes. Serum 25(OH)D levels were categorized into quartiles (#17.7, 17.8–24.5,
24.6–32.4, .32.4 ng/mL). Prediabetes was deﬁned as a 2-h glucose concentration of 140–199
mg/dL, or a fasting glucose concentration of 110–125 mg/dL, or an A1C value of 5.7–6.4%.
RESULTS—Lower serum 25(OH)D levels were associated with prediabetes after adjusting for
age, sex, race/ethnicity, season, geographic region, smoking, alcohol intake, BMI, outdoor phys-
icalactivity,milkconsumption, dietaryvitamin D, blood pressure,serum cholesterol,C-reactive
protein,andglomerularﬁltrationrate.Comparedwithquartile4of25(OH)D(referent),theodds
ratio of prediabetes associated with quartile 1 was 1.47 (95% CI 1.16–1.85; P =0 . 0 0 1f o rt re n d ).
Subgroup analyses examining the relation between 25(OH)D and prediabetes by sex, BMI, and
hypertension categories also showed a consistent positive association.
CONCLUSIONS—Lower serum 25(OH)D levels are associated with prediabetes in a repre-
sentative sample of U.S. adults.
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S
everalstudieshaveshownthatlower
25-hydroxyvitamin D (25[OH]D)
levels are related to an increased
risk of cardiovascular disease (CVD)
(1,2). Some evidence also suggests that
25(OH)D insufﬁciency may be involved
in the development of diabetes (3,4). In
animal models of diabetes, 25(OH)D de-
ﬁciency impaired insulin synthesis and
secretion, and pharmacologic doses of
1,25-dihydroxyvitamin D3 delayed the
onset of diabetes (5,6).
Unlike animal models, the results
have not been similarly consistent in
human studies (7). Although some epide-
miologic studies have reported a positive
association (8–10) between low serum
25(OH)D levels and diabetes, others did
not ﬁnd an independent association after
multivariable adjustment (11,12) for
confounders, or in subgroup analyses in
women (13). Scragg et al. (8) reported an
association between serum 25(OH)D lev-
els and diabetes in non-Hispanic whites
and Mexican Americans in the third Na-
tional Health and Nutrition Examina-
tion Survey (NHANES III), and Liu
etal.(9)reportedanassociationbetween
25(OH)D levels and type 2 diabetes in the
Framingham Study. Pittas et al. (11) re-
ported that dietary vitamin D was associ-
ated with diabetes in the Nurses’ Health
Study. A recent meta-analysis suggested
that there is insufﬁcient evidence to con-
clude an inverse association exists be-
tween 25(OH)D levels and diabetes (7).
Furthermore, reduced kidney function
isapotentialconfounderintheassociation
between 25(OH)D levels and diabetes
because it has been shown to cause low
25(OH)D levels due to a decrease in renal
1-a hydroxylase activity (14) as well as to
diabetes (15). Similarly, markers of in-
ﬂammation have been shown to be asso-
ciated with diabetes (16) and also with
low 25(OH)D levels (17). However, pre-
vious studies of serum 25(OH)D levels
and diabetes have not accounted for these
confounders.
Prediabetes is a stage earlier in the
hyperglycemia/diabetes continuum where
individuals are at increased risk of de-
veloping diabetes and where prevention
efforts, including lifestyle modiﬁcation
or pharmacologic intervention, have
been shown to be effective in preventing
ordelayingtheonsetofdiabetes(1,18).To
our knowledge, no previous study has
examined the association between serum
25(OH)D levels and prediabetes, so we
conducted this study in a nationally rep-
resentative sample of U.S. adults who
were free of clinical CVD and diabetes
after adjusting for potential confounders,
including serum C-reactive protein
(CRP) levels for systemic inﬂammation,
and estimated glomerular ﬁltration rate
(eGFR) from serum creatinine for kidney
function.
RESEARCH DESIGN AND
METHODS—The current study used
data from the NHANES III. A detailed
description of the NHANES III study
design and methods is available else-
where (19). Brieﬂy, the NHANES survey
includedastratiﬁedmultistageprobability
sample representative of the civilian
noninstitutionalized U.S. population. Se-
lection was based on counties, blocks,
households, and individuals within house-
holds, and included the oversampling
of non-Hispanic blacks and Mexican
Americans to provide stable estimates of
these groups.
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ORIGINAL ARTICLEThe current study consisted of par-
ticipants aged .20 years who were ran-
domly assigned to be examined in the
morning after an overnight fast. Serum
25(OH)D levels were measured in 18,883
participants who had surplus sera avail-
able. We excluded 1,883 subjects with di-
abetes, 952 with CVD, and 3,329 with
missing data for covariates included in
the multivariable model. This resulted in
12,719 participants without diabetes,
4,057 of whom had prediabetes.
Main outcome of interest: prediabetes
Plasma glucose was measured by a mod-
iﬁed hexokinase enzymatic method (20).
Glycosylated hemoglobin (A1C) was
measured using an ion-exchange high-
performance liquid chromatography
method using the Diamat Analyzer Sys-
tem (Hercules, CA). Prediabetes was de-
ﬁned as adults without diabetes who
had impaired glucose tolerance (2-h glu-
cose concentration of 140–199 mg/dL
[7.8–11.0 mmol/L]), or impaired fasting
glucose (fasting glucose concentration
110–25 mg/dL [5.6–6.9 mmol/L]), or
an A1C value of 5.7–6.4%, consistent
with recent American Diabetes Associa-
tion recommendations (1).
Exposure measurements
A questionnaire was used to assess age,
sex, race/ethnicity, geographic region,
smoking, alcohol intake (g/day), history
of diabetes, oral hypoglycemic intake or
insulin administration, and antihyperten-
sive medication use. Individuals who had
not smoked $100 cigarettes in their life-
times were considered never smokers;
those who had smoked $100 cigarettes
in their lifetimes were considered former
smokers if they answered negatively to
the question “Do you smoke now?”,a n d
current smokers if they answered afﬁr-
matively. BMI was calculated as weight
(kg)/height (m
2). Season of blood collec-
tion was assessed from the date of the re-
spondent’s physical examination. Dietary
vitamin D intake and milk consumption
was assessed from a single 24-h dietary
recall. Outdoor physical activity as a sur-
rogate for sunlight exposure was assessed
from self-reported physical activities
likely to be performed outdoors, including
walking, jogging or running, bicycling,
swimming, and garden/yard activity.
Rigorous procedures with quality
control checks were used in blood collec-
tion, as detailed in the NHANES “Labora-
tory Procedures Manual.” Measurements
ofserum25(OH)Dwereperformed at the
National Center for Environmental
Health, Centers for Disease Control and
Prevention (Atlanta, GA) using a radioim-
munoassay (RIA) kit (DiaSorin, Stillwater,
MN) (19). The interassay coefﬁcient of
variation was 15–25% for lower values
(20–62 nmol/L) and 14–18% for higher
values (86–143 nmol/L) (19). Serum
CRP was analyzed using a modiﬁcation
of the Behring Latex-Enhanced CRP assay
on the Behring Nephelometer Analyzer
System (Somerville, NJ). Serum total cho-
lesterol was measured enzymatically. Se-
rum creatinine was measured using a
modiﬁed kinetic Jaffe reaction on a Roche
Hitachi 737 analyzer (Indianapolis, IN),
and the NHANES values in NHANES III
were calibrated to the standard creatinine
values from the Cleveland Clinic Founda-
tion (CCF) laboratory, as recommended
previously (21). The eGFR was calculated
from serum creatinine level by using the
four-variableModiﬁcationofDietinRenal
Disease equation.
Statistical analysis
Serum levels of 25(OH)D were analyzed
both as a continuous and a categoric
variable. We categorized serum 25(OH)
D level as quartiles (#17.7, 17.8–24.5,
24.6–32.4, .32.4 ng/mL). We were in-
terested in the association between low
25(OH)D levels and prediabetes. The
odds ratio (OR) and 95% CI of prediabe-
tes for each lower serum 25(OH)D quar-
tile was calculated by taking the highest
quartile as the referent, using multivari-
able logistic regression models. We used
twomodels:age-,sex-,ethnicity-adjusted
model and the multivariable model, ad-
ditionally adjusting for season (January–
March, April–June, July–September,
October–December), geographic region
(Northeast, Midwest, South, West), smok-
ing (never smoker, former smoker, cur-
rentsmoker),alcoholintake(g/day),BMI
(kg/m
2), outdoor physical activity (yes,
no), milk consumption (yes, no), dietary
vitamin D (mg), hypertension (yes, no),
systolic blood pressure (mmHg), serum
total cholesterol (mg/dL), CRP (mg/dL),
and eGFR (mL/min/1.73 m
2).
Tests for trends were performed by
modeling serum 25(OH)D categories as
an ordinal variable. To examine the con-
sistency of the association, we performed
subgroupanalysesbyage,sex,geographic
region, season of blood draw, BMI, CRP,
eGFR, outdoor physical activity, dietary
intake of vitamin D, and hypertension.
We formally evaluated interactions be-
tween serum 25(OH)D levels and other
covariates such as age, sex, race/ethnicity,
geographic region, month of blood col-
lection, dietary intake of vitamin D, and
outdoor physical activity by including
cross-product interaction terms in the
corresponding multivariable models. Sam-
ple weights that account for the unequal
probabilities of selection, oversampling,
and nonresponse were applied for all
analyses using SUDAAN 8.0 (Research
Triangle Institute, Research Triangle Park,
NC)andSAS 9.2 (SASInstitute,Cary,NC)
software; SEs were estimated using the
Taylor series linearization method. All val-
ues presented are weighted to represent
the U.S. civilian population.
To examine the dose-response rela-
tionship of the observed association be-
tween the serum 25(OH)D level and
prediabetes without linearity assumptions,
we used ﬂexible nonparametric logistic
regression using the generalized additive
modeling approach with the R system
for statistical computing (Comprehensive
R Archive Network, http://www.CRAN.
R-project.org) to calculate odds of predia-
betes, adjusting for all covariates in the
multivariable model. The predicted odds
ofprediabetes werethen plotted against in-
creasing 25(OH)D levels (log scale).
In a supplementary analysis, we
repeated the multivariable model ad-
ditionally adjusting for A1C. Second, to
examine whether the association between
25(OH)D and prediabetes is confounded
by central obesity, we adjusted for waist
circumference, a surrogate for central
obesityinthemultivariablemodel.Third,
we examined the association between
serum 25(OH)D and prediabetes using
clinically relevant categories of serum
25(OH)D (,10, 10–20, 21–30, and
.30 ng/mL).
RESULTS—Among 12,719 partici-
pants included for the current analysis,
4,057 had prediabetes. Those in the
lowest quartile of 25(OH)D were more
likely to be a current smoker and obese;
have higher levels of diastolic blood pres-
sure, CRP, and eGFR; and were less likely
to be women, non-Hispanic white, cur-
rent drinkers, and physically active (data
not shown).
As reported in Table 1, compared
with those with normal glucose levels, in-
dividuals with prediabetes were more
likely to be older, former/current smok-
ers, overweight and obese; have higher
levels of systolic and diastolic blood pres-
sure, total cholesterol, and CRP; were less
likely to be women, non-Hispanic white,
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and have lower levels of eGFR (Table 1).
AsreportedinTable2,lower25(OH)D
levels were associated with prediabetes in
both the age-, sex-, ethnicity-adjusted as
well as the multivariable-adjusted model
that adjusted for various confounders,
including CRP levels and eGFR. Models
evaluating trend in this association were
also statistically signiﬁcant (P , 0.001).
As reported in Table 3, we observed
an overall statistically signiﬁcant positive
association between lower 25(OH)D lev-
els and prediabetes within subgroups of
age, sex, race/ethnicity, geographic re-
gion, season of blood draw, BMI, CRP,
eGFRlevels,outdoorphysicalactivity,di-
etary intake of vitamin D, and hyperten-
sion, and the ORs ranged from 0.96 to
1.24 (all P . 0.1 for interaction). Al-
though no statistically signiﬁcant interac-
tion was found between serum 25(OH)D
and the odds of prediabetes for race/
ethnicity, the CIs in Table 3 show that
the ORs among non-Hispanic whites
were signiﬁcant, whereas the ORs among
non-Hispanic blacks, Mexican Americans,
and others were not signiﬁcant. In non-
parametric graphic models, we observed a
continuous inverse association between
serum 25(OH)D level and prediabetes,
without any threshold effect (Fig. 1).
In a supplementary analysis, we ex-
amined the association between lower se-
rum 25(OH)D levels and prediabetes
additionally adjusting for A1C levels to the
multivariable-adjusted model in Table 2;
the association was slightly attenuated
but still present. The multivariable OR
(95% CI) of prediabetes per 10-unit de-
crease in serum 25(OH)D levels was
1.08 (1.00–1.18).
Second, when we added waist cir-
cumference as a covariate, instead of BMI
in the multivariable model in Table 2, the
results were slightly accentuated. Com-
pared with quartile 4, the multivariable
OR (95% CI) of prediabetes was 1.16
(0.99–1.36) in quartile 3, 1.38 (1.31–
2.05) in quartile 2, and 1.64 (1.31–
2.05) in quartile 1 of serum 25(OH)D.
Third, when we repeated the multi-
variable analysis in Table 2 using clini-
cally relevant categories of 25(OH)D
compared with those with 25(OH)D
levels of .30 ng/mL, the multivariable
OR (95% CI) of prediabetes was 1.22
(1.06–1.42), 1.35 (1.11–1.64), and 1.58
(1.04–2.40) among those with 25(OH)D
levels of 21–30, 10–20, and ,10 ng/mL,
respectively (P = 0.002 for trend).
CONCLUSIONS—Lower serum
25(OH)D levels were positively associ-
ated with prediabetes in this representa-
tivesampleofU.S.adults.Theassociation
between 25(OH)D and prediabetes was
independent of confounding factors, in-
cluding age, sex, race/ethnicity, smoking,
alcohol intake, BMI, physical activity,
hypertension, systolic blood pressure,
serum total cholesterol, CRP levels, and
eGFR. The association between serum
25(OH)D and prediabetes was also con-
sistently present in subgroup analyses by
sex, BMI, and hypertension. Our results
Table 1—Characteristics of the study population by prediabetes status*
Characteristic
Prediabetes
absent
Prediabetes
present P†
Unweighted sample size 8,662 4,057
Age (years) 39.33 6 0.36 51.13 6 0.61 ,0.0001
Female (%) 55.67 6 0.69 42.96 6 1.29 ,0.0001
Smoking categories (%) ,0.0001
Never smoker 50.29 6 1.07 42.02 6 1.02
Former smoker 21.03 6 0.83 28.42 6 0.92
Current smoker 28.68 6 0.99 29.55 6 1.07
Current drinker (%) 59.18 6 1.28 49.74 6 2.00 ,0.0001
BMI (kg/m
2) ,0.0001
,25 51.86 6 0.93 33.10 6 1.27
25–29.9 31.16 6 0.71 37.61 6 1.01
$30 16.98 6 0.80 29.29 6 0.90
Race/ethnicity (%) ,0.0001
Non-Hispanic white 79.08 6 1.28 71.40 6 1.74
Non-Hispanic black 8.64 6 0.54 14.27 6 0.89
Mexican American 4.99 6 0.42 5.49 6 0.55
Others 7.30 6 0.88 8.84 6 1.28
Outdoor physical activity (%) 54.28 6 1.14 48.07 6 1.37 ,0.0001
Hypertension (%) 22.02 6 0.84 41.14 6 1.28 ,0.0001
Blood pressure (mmHg)
Systolic 117.89 6 0.31 128.46 6 0.58 ,0.0001
Diastolic 73.13 6 0.22 76.80 6 0.27 ,0.0001
Total cholesterol (mg/dL) 197.19 6 0.80 215.76 6 1.13 ,0.0001
HDL cholesterol (mg/dL) 58.10 6 3.27 56.06 6 2.89 0.08
Serum CRP (mg/dL) 0.35 6 0.01 0.47 6 0.02 ,0.0001
eGFR (mL/min/1.73 m
2) 96.27 6 0.53 87.78 6 0.58 ,0.0001
Data are means 6 SD unless otherwise indicated. *All values presented are weighted to represent the U.S.
civilianpopulation,1988–1994.†Pvaluerepresentsdifferencesinmeans(SD)orproportions,usingANOVA
or x
2 test.
Table 2—Association between serum 25(OH)D levels and prediabetes
Serum 25(OH)D
level
N at risk
(prediabetes
cases)
Age-, sex-,
ethnicity-adjusted
OR (95% CI)*
Multivariable
OR
(95% CI)*†
Quartile IV (.32.4 ng/mL) 3,185 (892) 1.00 (ref) 1.00 (ref)
Quartile III (24.6–32.4 ng/mL) 3,171 (1,008) 1.15 (0.99–1.33) 1.10 (0.94–1.30)
Quartile II (17.8–24.5 ng/mL) 3,215 (1,083) 1.43 (1.19–1.71) 1.24 (1.03–1.51)
Quartile I (#17.7 ng/mL) 3,148 (1,074) 1.73 (1.41–2.13) 1.47 (1.16–1.85)
P (trend) ,0.0001 0.001
OR for 10-unit decrease in 25(OH)D 12,719 (4,057) 1.21 (1.13–1.28) 1.13 (1.06–1.21)
*OR values presented are weighted to represent the U.S. civilian population, 1988–1994. †Adjusted for age
(years), sex (men, women), race/ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans,
others), geographic region (Northeast, Midwest, South, West), season of blood drawn (January–March,
April–June, July–September, October–December), smoking categories (never, former, current), current
drinker(yes,no),milkconsumption(yes,no),BMI(kg/m
2),dietaryvitaminD(mg),outdoorphysicalactivity
(yes, no), hypertension (yes, no), systolic blood pressure (mmHg), total cholesterol (mg/dL),high-sensitivity
CRP level (mg/dL), eGFR (mL/min/1.73 m
2).
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25-Hydroxyvitamin D and prediabetescontribute to the existing literature on the
effect of low serum 25(OH)D on diabetes
by demonstrating for the ﬁrst time that
25(OH)D levels are independently asso-
ciated with prediabetes, a stage in the
disease continuum where diabetes pre-
vention efforts have been shown to be
effective in preventing the onset of di-
abetes (1,18).
Previous reports have shown that
lower serum 25(OH)D levels are related
toCVDandCVDmortality(2,22).Several
lines of recent evidence also suggest that
25(OH)D insufﬁciency may be involved
in the risk of developing diabetes (3,4), a
risk factor for CVD. In animal models,
low levels of 25(OH)D have been shown
to impair insulin synthesis and secretion,
andtreatmentwith25(OH)Dhas,inturn,
been shown to delay the onset of diabetes
(5,6).
However, the results from human
studies have not been similarly consistent
(7). First, although some epidemiologic
studies have reported a positive associa-
tion(8–10)betweenlowserum25(OH)D
levels and diabetes, others did not ﬁnd
an association after multivariable adjust-
ment (11,12) or in an analysis among
women (13). Pittas et al. (7), in a recent
meta-analysis, concluded that evidence
was insufﬁcient to support an inverse as-
sociation between 25(OH)D levels and
diabetes. Also, to our knowledge, the as-
sociation between serum 25(OH)D levels
and prediabetes has not been previously
examined.
Table 3—Association between serum 25(OH)D levels and prediabetes, within selected
subgroups
Subgroup of
interest
N at risk
(cases)
Multivariable OR (95% CI)
for 10-unit decrease
in serum 25(OH)D*†
P
(interaction)‡
Age
,60 years 9,558 (2,383) 1.15 (1.07–1.24) 0.91
$60 years 3,161 (1,674) 1.04 (0.93–1.17)
Sex
Women 6,850 (1,860) 1.15 (1.05–1.25) 0.83
Men 5,869 (2,197) 1.13 (1.04–1.24)
Race/ethnicity
Non-Hispanic white 5,275 (1,567) 1.09 (1.02–1.17) 0.93
Non-Hispanic black 3,435 (1,282) 1.00 (0.89–1.12)
Mexican American 3,491 (1,033) 1.00 (0.88–1.15)
Others 518 (175) 1.13 (0.85–1.50)
Geographic region
Northeast 1,720 (525) 1.23 (1.08–1.40) 0.48
Midwest 2,513 (788) 1.12 (1.01–1.25)
South 5,440 (1,855) 1.16 (1.03–1.30)
West 3,046 (889) 1.01 (0.91–1.11)
Season
January–March 3,325 (1,097) 1.04 (0.93–1.17) 0.18
April–June 3,332 (1,023) 0.96 (0.89–1.04)
July–September 3,134 (960) 1.18 (1.11–1.26)
October–December 2,928 (977) 1.24 (1.08–1.41)
BMI (kg/m
2)
,25 5,365 (1,226) 1.08 (0.97–1.21) 0.88
25–29.9 4,408 (1,561) 1.17 (1.05–1.30)
$30 2,946 (1,270) 1.15 (1.00–1.33)
Hypertension
Yes 4,002 (1,831) 1.13 (1.02–1.25) 0.65
No 8,717 (2,226) 1.13 (1.04–1.23)
CRP (mg/dL)
,0.3 8,797 (2,477) 1.11 (1.02–1.19) 0.24
$0.3 3,922 (1,580) 1.19 (1.06–1.34)
eGFR (mL/min/1.73 m
2)
,95 6,239 (2,483) 1.13 (1.04–1.22) 0.74
$95 6,480 (1,574) 1.13 (1.01–1.27)
Outdoor physical activity
Yes 9,116 (2,847) 1.13 (1.06–1.21) 0.99
No 3,603 (1,210) 1.11 (0.96–1.30)
Dietary vitamin D (mg)
,4.6 7,742 (2,436) 1.07 (0.96–1.20) 0.28
$4.6 4,977 (1,621) 1.20 (1.10–1.30)
*OR values presented are weighted to represent the U.S. civilian population, 1988–1994. †Adjusted for age
(years), sex (men, women), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American,
others), geographic region (Northeast, Midwest, South, West), season blood drawn (January–March, April–
June, July–September, October–December), smoking categories (never, former, current), current drinker
(yes, no), milk consumption (yes, no), BMI (kg/m
2), dietary vitamin D (mg), outdoor physical activity (yes,
no), hypertension (yes, no), systolic blood pressure (mmHg), total cholesterol (mg/dL), CRP level (mg/dL),
eGFR (mL/min/1.73 m
2). ‡P value associated with the cross-product interaction term between the corre-
sponding stratiﬁcation variable and the 25(OH)D variable in the multivariable model.
Figure 1—Multivariable-adjusted odds of
prediabetes according to serum 25(OH)D level
(ng/mL). The predicted odds of prediabetes
from nonparametric logistic regression (solid
line) are shown with 95% CI (dashedlines)for
the nonparametric logistic regression esti-
mates. The nonparametric logistic regression
was adjusted for age (years), sex (men,
women), race/ethnicity (non-Hispanic whites,
non-Hispanic blacks, Mexican Americans,
others), geographic region (Northeast, Mid-
west, South, West), season of blood drawn
(January–March, April–June, July–September,
October–December),smokingcategories(never,
former,current),currentdrinker(yes,no),milk
consumption (yes, no), BMI (kg/m
2), dietary
vitamin D (mg), outdoor physical activity (yes,
no), hypertension (yes, no), systolic blood
pressure(mmHg),totalcholesterol(mg/dL),
high-sensitivity CRP level (mg/dL), eGFR
(mL/min/1.73 m
2). x axis: Serum 25(OH)D
level (ng/mL). y1 axis: Predicted odds of pre-
diabetes plotted in log scale. y2 axis: Partici-
pant number for each serum 25(OH)D level.
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Shankar, Sabanayagam, and KalidindiThe few intervention studies that
have evaluated the effect of 25(OH)D
supplementation on glucose regulation
havealsoshownmixedresults.Inasmall,
short-term clinical trial, treatment with
25(OH)D3 improved insulin sensitivity
and ﬁrst-phase insulin secretion in the
intervention group (23). In a placebo-
controlled trial of nondiabetic subjects
with impaired fasting glucose at baseline,
treatment with 25(OH)D3 and calcium
attenuated a rise in fasting glucose and
progression of insulin resistance (24). In
contrast, treatment with 25(OH)D3 and
calcium in the Women’s Health Initiative
trial involving postmenopausal women
did not reduce the risk of developing di-
abetes (25). However, this trial deﬁned
diabetes by self-report and not by blood
glucose measurements, and the 25(OH)
D3 doses were lower than in other stud-
ies. In the face of our ﬁnding of a positive
association between low levels of serum
25(OH)D and prediabetes, results from
these 25(OH)D intervention studies indi-
rectly suggest that 25(OH)D3 supple-
mentation may be potentially beneﬁcial
in preventing or delaying diabetes devel-
opment in individuals with prediabetes.
In the current study, low serum
25(OH)D levels were positively associ-
ated with prediabetes. The magnitude of
the association observed between low
25(OH)D and prediabetes, its persistence
even after multivariable adjustment, and
the consistency of these ﬁndings in sub-
group analyses by sex, BMI categories,
andhypertension,suggestthattheseﬁnd-
ings are less likely to be due to chance.
Reduced GFR is a potential con-
founder in the association between serum
25(OH)D levels and diabetes because it
has been shown to cause low 25(OH)D
levels (14), as well as to cause diabetes
(15). Similarly, CRP levels were associ-
ated with diabetes (16) and with low
25(OH)D levels (17). However, previous
studies of serum 25(OH)D levels and
diabetes did not account for the con-
founding effect of reduced kidney func-
tion or systemic inﬂammation. The
observed association between low serum
25(OH)D levels and prediabetes was
attenuated in the current study but still
persisted after adjustment for eGFR and
CRP levels in the multivariable model,
suggesting the association is independent
of these processes.
In the current study, the positive as-
sociation between serum 25(OH)D and
prediabetes was signiﬁcant only in non-
Hispanic whites but not in non-Hispanic
blacks, Mexican Americans, and others.
Ethnic variations in 25(OH)D levels
have been recognized in the U.S.: non-
Hispanic whites have higher levels of
25(OH)D than Mexican Americans and
non-Hispanic blacks (19). Our results are
also consistent with the previous analyses
of NHANES III data by Scragg et al. (8),
who reported an inverse association be-
tween 25(OH)D and undiagnosed dia-
betes among non-Hispanic whites and
Mexican Americans but no association
among non-Hispanic blacks. The associ-
ation between serum 25(OH)D and pre-
diabetes among non-Hispanic whites
only suggests that non-Hispanic whites
may be more sensitive to 25(OH)D deﬁ-
ciency compared with other races and
ethnicities.
The main strengths of our study in-
clude its population-based nature, in-
clusion of a representative multiethnic
sample, adequate sample size, and the
availability of data on confounders for
multivariable adjustment.
The main limitation of our study is
the cross-sectional nature of NHANES. It
ispossiblethatourresultscouldbebiased
by residual confounding by variables,
including the use of vitamin D supple-
ments and parathyroid hormone levels.
Further, the high coefﬁcient of variation
at lower values of 25(OH)D suggests that
there may be measurement error and
therefore exposure misclassiﬁcation of
25(OH)D.
In summary, in a representative sam-
ple of U.S. adults, low serum levels of
25(OH)D were positively associated with
prediabetes among subjects without di-
abetes. This association was independent
of confounding factors, including BMI,
blood pressure, serum cholesterol, CRP
levels, and eGFR. Because prediabetes is
a stage in the disease continuum where
diabetes prevention has been shown to be
effective (1,18), it would be of public
health relevance to see if vitamin D sup-
plementation in this stage can help to
prevent or delay the onset of diabetes.
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